- Home
- LBTYA vs AKRO Comparison
LBTYA vs AKRO Comparison
Compare LBTYA & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LBTYA | AKRO |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Cable & Other Pay Television Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 4.5B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | LBTYA | AKRO |
|---|---|---|
| Price | $11.29 | $54.54 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | $14.77 | ★ $73.56 |
| AVG Volume (30 Days) | ★ 1.8M | 1.7M |
| Earning Date | 10-30-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,770,600,000.00 | N/A |
| Revenue This Year | $13.22 | N/A |
| Revenue Next Year | $1.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 170.50 | N/A |
| 52 Week Low | $9.03 | $21.34 |
| 52 Week High | $13.91 | $58.40 |
Technical Indicators
Market Signals| Indicator | LBTYA | AKRO |
|---|---|---|
| Relative Strength Index (RSI) | 57.07 | 66.54 |
| Support Level | $10.99 | $54.22 |
| Resistance Level | $11.68 | $54.70 |
| Average True Range (ATR) | 0.29 | 0.14 |
| MACD | 0.04 | -0.11 |
| Stochastic Oscillator | 70.00 | 64.18 |
Price Performance
Historical ComparisonAbout LBTYA Liberty Global Ltd.
Liberty Global is a holding company with interests in European telecom companies in the UK, the Netherlands, Belgium, Ireland, and Slovakia. Liberty owns the main cable network in each of these geographies and has pursued a strategy since 2016 to merge or partner with mobile network operators to be able to offer converged services. Liberty also owns minority stakes in other media, entertainment, and cloud companies.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.